Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Erythrodermic psoriasis (EP) is a severe and complex form of psoriasis. While risankizumab, an interleukin (IL)-23 inhibitor, has demonstrated efficacy in patients with moderate-to-severe plaque psoriasis, its effectiveness in patients with EP remains less explored. The literature contains several...

Full description

Bibliographic Details
Published in:	Dermatology Reports
Main Authors:	Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini
Format:	Article
Language:	English
Published:	PAGEPress Publications 2025-07-01
Subjects:	Psoriasis risankizumab erythrodermic psoriasis safety efficacy
Online Access:	https://www.pagepress.org/journals/dr/article/view/10379

Similar Items

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023-12-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024-06-01)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)

Rapidly and successful improvement of nail psoriasis with risankizumab
by: Diego Orsini, et al.
Published: (2023-10-01)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
by: Potestio L, et al.
Published: (2023-08-01)

A nomogram diagnostic cardiovascular disease in patients with erythrodermic psoriasis in Chinese
by: Yue-Min Zou, et al.
Published: (2023-06-01)

Adalimumab-Induced Erythrodermic Psoriasis Associated with Alopecia in a Patient with Palmoplantar Pustulosis
by: Ying Wang, et al.
Published: (2024-04-01)

Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report
by: Chen W, et al.
Published: (2022-09-01)

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report
by: Lu X, et al.
Published: (2023-07-01)

Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study
by: Yachen Wang, et al.
Published: (2025-07-01)

Biologic anti-IL17 drugs in erythrodermic psoriasisCapsule Summary
by: Alessandro Falco, MD, et al.
Published: (2024-09-01)

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis
by: Huijuan Shi, et al.
Published: (2024-05-01)

Erythrodermic Psoriasis with Superimposed Fungal Infection-a Presentation in the Emergency Room
by: Muhammad Akbar Baig, et al.
Published: (2018-03-01)

Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
by: Song B, et al.
Published: (2024-08-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Respiratory Distress Syndrome Associated with Erythrodermic Psoriasis
by: Lamya Noure, et al.
Published: (2021-02-01)

Ustekinumab Treatment of Erythrodermic Psoriasis Occurring after Physical Stress: A Report of Two Cases
by: Rosita Saraceno, et al.
Published: (2013-09-01)

Heart failure in erythrodermic psoriasis: a retrospective study of 225 patients
by: Chao Wu, et al.
Published: (2023-08-01)

Efficacy and safety of biologics in erythrodermic psoriasis: a systematic review and single-arm meta-analysis
by: Lingjie Gao, et al.
Published: (2025-10-01)

Ustekinumab is effective and safe in the long‐term treatment of erythrodermic psoriasis: Multicenter study in daily practice
by: Clara Plana, et al.
Published: (2024-06-01)

Risankizumab in Oncologic Patients With Psoriasis: A Case Series
by: Michela Magnano, et al.
Published: (2025-06-01)

Prevalence of Metabolic Syndrome in Chinese Patients With Erythrodermic Psoriasis: A Case-Control Study
by: An-ran Ma, et al.
Published: (2021-12-01)

Risankizumab in the treatment of psoriasis – literature review
by: Katarzyna Banaszczyk
Published: (2019-06-01)

Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease
by: Aya Fadel, et al.
Published: (2025-06-01)

Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach
by: Xu JM, et al.
Published: (2025-07-01)

Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study
by: Yukari Okubo, et al.
Published: (2025-08-01)

Possible effects of anti-interleukin-17 agents on erythrodermic psoriasis with thymoma: A case report
by: Qiuyu Jia, MD, PhD, et al.
Published: (2025-10-01)

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
by: Diego Orsini, et al.
Published: (2023-12-01)

Dupilumab‐Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment Approach
by: Joe Khodeir, et al.
Published: (2024-11-01)

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024-12-01)

New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab
by: O. V. Zhukova, et al.
Published: (2021-06-01)

Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
by: Diego Orsini, et al.
Published: (2024-12-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Successful Treatment with Secukinumab in an Erythrodermic Psoriasis Patient with End-Stage Kidney Disease on Hemodialysis: A Case Report
by: Zhang S, et al.
Published: (2025-10-01)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023-06-01)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021-11-01)

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison
by: Leyla Baykal Selçuk, et al.
Published: (2025-04-01)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil
by: Tania F. Cestari, et al.
Published: (2025-04-01)

Risankizumab: Daily Practice Experience of High Need Patients
by: Alexandra M. G. Brunasso, et al.
Published: (2023-06-01)